Showing results (381-390 of 411) with videos related to
Sort By:
Pageof 42
Practical Radiation Oncology|January 31, 2016
Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice reviewCharles S Mayo, Thomas M Pisansky, Ivy A Petersen, et al.Cancer|March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinomaLisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.American Journal of Clinical Oncology|January 28, 2020
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical TrialRoss A Abrams, Kathryn A Winter, Howard Safran, et al.Advances in Radiation Oncology|June 16, 2018
Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704William F Regine, Kathryn Winter, Ross A Abrams, et al.The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.International Journal of Radiation Oncology, Biology, Physics|October 12, 2014
Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancerAkila N Viswanathan, Beth Erickson, David K Gaffney, et al.The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.Radiation Oncology (London, England)|October 23, 2012
The clinical case for proton beam therapyRobert L Foote, Scott L Stafford, Ivy A Petersen, et al.Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.Pageof 42